m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03982)
Name
LY3415244
Status
Phase 1
TTD Drug ID
DC8HR6
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Hepatitis A virus cellular receptor 2 (TIM3)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3415244. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY3415244 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [1], [2]
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3415244. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of LY3415244 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [1], [2]
Programmed cell death 1 ligand 1 (PD-L1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [3], [4]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [3], [4]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [4], [6]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [3], [4]
References
Ref 1 Roles of the m(6)A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol. 2022 Apr 26;13:798583. doi: 10.3389/fimmu.2022.798583. eCollection 2022.
Ref 2 Clinical pipeline report, company report or official report of BeiGene.
Ref 3 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 4 Clinical pipeline report, company report or official report of Innovent.
Ref 5 METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022 Feb 23;21(1):60. doi: 10.1186/s12943-021-01447-y.
Ref 6 M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021 Sep 15;81(18):4778-4793. doi: 10.1158/0008-5472.CAN-21-0468. Epub 2021 Jul 23.